Indications and Results of HLA-Identical Sibling Hematopoietic Cell Transplantation for Sickle Cell Disease

Biology of Blood and Marrow Transplantation

Volumn 22, Issue 2, 2016, Pages 207-211

  Walters, Mark C ^a   De Castro, Laura M ^b   Sullivan, Keith M ^c   Krishnamurti, Lakshmanan ^d   Kamani, Naynesh ^e   Bredeson, Christopher ^f   Neuberg, Donna ^g   Hassell, Kathryn L ^h   Farnia, Stephanie ⁱ   Campbell, Andrew ^j   Petersdorf, Effie ^k  

^a CHILDREN S HOSPITAL OAKLAND   (United States)

^b UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

^d EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e AABB   (United States)

^f OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^g DANA FARBER CANCER INSTITUTE   (United States)

^h UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

ⁱ Blood and Marrow Transplant Program ^*  (United States)

^j UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^k UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

more..

Author keywords

Children; Hematopoietic cell transplant; HLA identical sibling; Risks; Sickle cell anemia; Transplant related complications

Indexed keywords

ALEMTUZUMAB; BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; FLUDARABINE; HLA ANTIGEN; HYDROXYUREA; IMMUNOSUPPRESSIVE AGENT; MELPHALAN; METHOTREXATE; MYCOPHENOLATE MOFETIL; PREDNISONE; TACROLIMUS; THIOTEPA; THYMOCYTE ANTIBODY; TREOSULFAN;

ADULT; CELL TRANSPLANTATION; CHILD; EVENT FREE SURVIVAL; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC CELL TRANSPLANTATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; OVERALL SURVIVAL; REVIEW; SIBLING; SICKLE CELL ANEMIA; ADOLESCENT; ANEMIA, SICKLE CELL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOCOMPATIBILITY TEST; PROCEDURES; QUALITY OF LIFE; RISK FACTOR; TRANSPLANTATION CONDITIONING;

ADOLESCENT; ANEMIA, SICKLE CELL; CHILD; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOCOMPATIBILITY TESTING; HUMANS; QUALITY OF LIFE; RISK FACTORS; SIBLINGS; TRANSPLANTATION CONDITIONING;

EID: 84958239480     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2015.10.017     Document Type: Review

References (45)

1. Bernaudin F., Socie G., Kuentz M., et al. Long-term results of related myeloablative stem-cell transplantation to cure sickle cell disease. Blood 2007, 110:2749-2756.
2. Vermylen C., Cornu G., Ferster A., et al. Haematopoietic stem cell transplantation for sickle cell anaemia: the first 50 patients transplanted in Belgium. Bone Marrow Transplant 1998, 22:1-6.
3. van Besien K., Koshy M., Anderson-Shaw L., et al. Allogeneic stem cell transplantation for sickle cell disease. A study of patients' decisions. Bone Marrow Transplant 2001, 28:545-549.
4. Walters M.C., Patience M., Leisenring W., et al. Barriers to bone marrow transplantation for sickle cell anemia. Biol Blood Marrow Transplant 1996, 2:100-104.
5. Mentzer W.C., Heller S., Pearle P.R., et al. Availability of related donors for bone marrow transplantation in sickle cell anemia. Am J Pediatr Hematol Oncol 1994, 16:27-29.
6. Hankins J., Hinds P., Day S., et al. Therapy preference and decision-making among patients with severe sickle cell anemia and their families. Pediatr Blood Cancer 2007, 48:705-710.
7. Roth M., Krystal J., Manwani D., et al. Stem cell transplant for children with sickle cell anemia: parent and patient interest. Biol Blood Marrow Transplant 2012, 18:1709-1715.
8. Omondi N.A., Ferguson S.E., Majhail N.S., et al. Barriers to hematopoietic cell transplantation clinical trial participation of african american and black youth with sickle cell disease and their parents. J Pediatr Hematol Oncol 2013, 35:289-298.
9. Hsieh M.M., Fitzhugh C.D., Weitzel R.P., et al. Nonmyeloablative HLA-matched sibling allogeneic hematopoietic stem cell transplantation for severe sickle cell phenotype. JAMA 2014, 312:48-56.
10. Walters M.C., Hardy K., Edwards S., et al. Pulmonary, gonadal, and central nervous system status after bone marrow transplantation for sickle cell disease. Biol Blood Marrow Transplant 2010, 16:263-272.
11. Platt O.S., Brambilla D.J., Rosse W.F., et al. Mortality in sickle cell disease. Life expectancy and risk factors for early death. N Engl J Med 1994, 330:1639-1644.
12. Quinn C.T., Rogers Z.R., McCavit T.L., Buchanan G.R. Improved survival of children and adolescents with sickle cell disease. Blood 2010, 115:3447-3452.
13. Telfer P., Coen P., Chakravorty S., et al. Clinical outcomes in children with sickle cell disease living in England: a neonatal cohort in East London. Haematologica 2007, 92:905-912.
14. Powars D., Weidman J.A., Odom-Maryon T., et al. Sickle cell chronic lung disease: prior morbidity and the risk of pulmonary failure. Medicine 1988, 67:66-76.
15. Lucarelli G., Isgro A., Sodani P., et al. Hematopoietic SCT for the Black African and non-Black African variants of sickle cell anemia. Bone Marrow Transplant 2014, 49:1376-1381.
16. Dedeken L., Le P.Q., Azzi N., et al. Haematopoietic stem cell transplantation for severe sickle cell disease in childhood: a single centre experience of 50 patients. Br J Haematol 2014, 165:402-408.
17. Bhatia M., Jin Z., Baker C., et al. Reduced toxicity, myeloablative conditioning with BU, fludarabine, alemtuzumab and SCT from sibling donors in children with sickle cell disease. Bone Marrow Transplant 2014, 49:913-920.
18. Majumdar S., Robertson Z., Robinson A., et al. Outcome of hematopoietic cell transplantation in children with sickle cell disease, a single center's experience. Bone Marrow Transplant 2010, 45:895-900.
19. McPherson M.E., Hutcherson D., Olson E., et al. Safety and efficacy of targeted busulfan therapy in children undergoing myeloablative matched sibling donor BMT for sickle cell disease. Bone Marrow Transplant 2011, 46:27-33.
20. Strocchio L., Zecca M., Comoli P., et al. Treosulfan-based conditioning regimen for allogeneic haematopoietic stem cell transplantation in children with sickle cell disease. Br J Haematol 2015, 169:726-736.
21. King A.A., Kamani N., Bunin N., et al. Successful matched sibling donor marrow transplantation following reduced intensity conditioning in children with hemoglobinopathies. Am J Hematol 2015, 90:1093-1098.
22. Gluckman E. Allogeneic transplantation strategies including haploidentical transplantation in sickle cell disease. Hematology Am Soc Hematol Educ Program 2013, 2013:370-376.
23. Locatelli F., Kabbara N., Ruggeri A., et al. Outcome of patients with hemoglobinopathies given either cord blood or bone marrow transplantation from an HLA-identical sibling. Blood 2013, 122:1072-1078.
24. Angelucci E., Matthes-Martin S., Baronciani D., et al. Hematopoietic stem cell transplantation in thalassemia major and sickle cell disease: indications and management recommendations from an international expert panel. Haematologica 2014, 99:811-820.
25. Yawn B.P., Buchanan G.R., Afenyi-Annan A.N., et al. Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members. JAMA 2014, 312:1033-1048.
26. Le P.Q., Gulbis B., Dedeken L., et al. Survival among children and adults with sickle cell disease in Belgium: benefit from hydroxyurea treatment. Pediatr Blood Cancer 2015, 62:1956-1961.
27. Dovey S., Krishnamurti L., Sanfilippo J., et al. Oocyte cryopreservation in a patient with sickle cell disease prior to hematopoietic stem cell transplantation: first report. J Assist Reprod Genet 2012, 29:265-269.
28. Demeestere I., Simon P., Dedeken L., et al. Live birth after autograft of ovarian tissue cryopreserved during childhood. Hum Reprod 2015, 30:2107-2109.
29. Powars D.R., Chan L.S., Hiti A., et al. Outcome of sickle cell anemia: a 4-decade observational study of 1056 patients. Medicine 2005, 84:363-376.
30. Elmariah H., Garrett M.E., De Castro L.M., et al. Factors associated with survival in a contemporary adult sickle cell disease cohort. Am J Hematol 2014, 89:530-535.
31. Steinberg M.H., McCarthy W.F., Castro O., et al. The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: A 17.5 year follow-up. Am J Hematol 2010, 85:403-408.
32. Ataga K.I., Moore C.G., Jones S., et al. Pulmonary hypertension in patients with sickle cell disease: a longitudinal study. Br J Haematol 2006, 134:109-115.
33. De Castro L.M., Jonassaint J.C., Graham F.L., et al. Pulmonary hypertension associated with sickle cell disease: clinical and laboratory endpoints and disease outcomes. Am J Hematol 2008, 83:19-25.
34. Gladwin M.T., Sachdev V., Jison M.L., et al. Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. N Engl J Med 2004, 350:886-895.
35. Machado R.F., Barst R.J., Yovetich N.A., et al. Hospitalization for pain in patients with sickle cell disease treated with sildenafil for elevated TRV and low exercise capacity. Blood 2011, 118:855-864.
36. Sachdev V., Kato G.J., Gibbs J.S., et al. Echocardiographic markers of elevated pulmonary pressure and left ventricular diastolic dysfunction are associated with exercise intolerance in adults and adolescents with homozygous sickle cell anemia in the United States and United Kingdom. Circulation 2011, 124:1452-1460.
37. Rotz S.J., O'Riordan M.A., Kim C., et al. Traffic light: prognosis-based eligibility for clinical trials of hematopoietic SCT in adults with sickle cell anemia. Bone Marrow Transplant 2015, 50:918-923.
38. Fitzhugh C.D., Lauder N., Jonassaint J.C., et al. Cardiopulmonary complications leading to premature deaths in adult patients with sickle cell disease. Am J Hematol 2010, 85:36-40.
39. Bernardo M.E., Piras E., Vacca A., et al. Allogeneic hematopoietic stem cell transplantation in thalassemia major: results of a reduced-toxicity conditioning regimen based on the use of treosulfan. Blood 2012, 120:473-476.
40. Kuentz M., Robin M., Dhedin N., et al. Is there still a place for myeloablative regimen to transplant young adults with sickle cell disease?. Blood 2011, 118:4491-4492. author reply 4492-4493.
41. Hsieh M.M., Kang E.M., Fitzhugh C.D., et al. Allogeneic hematopoietic stem-cell transplantation for sickle cell disease. N Engl J Med 2009, 361:2309-2317.
42. Horan J.T., Liesveld J.L., Fenton P., et al. Hematopoietic stem cell transplantation for multiply transfused patients with sickle cell disease and thalassemia after low-dose total body irradiation, fludarabine, and rabbit anti-thymocyte globulin. Bone Marrow Transplant 2005, 35:171-177.
43. Iannone R., Casella J.F., Fuchs E.J., et al. Results of minimally toxic nonmyeloablative transplantation in patients with sickle cell anemia and beta-thalassemia. Biol Blood Marrow Transplant 2003, 9:519-528.
44. Krishnamurti L., et al. Pilot Investigation of Bone Marrow Transplantation in Adults with Severe Sickle Cell Disease (STRIDE). Blood 2015, 126:543.
45. Majhail N.S., Farnia S.H., Carpenter P.A., et al. Indications for autologous and allogeneic hematopoietic cell transplantation: guidelines from the American Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant 2015, 21:1863-1869.